Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
21 oct. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
08 oct. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
01 oct. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
18 sept. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
04 sept. 2024 04h01 HE
|
Mainz BioMed NV
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
25 juil. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
09 juil. 2024 03h01 HE
|
Mainz BioMed NV
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
02 juil. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Provides Half Year 2024 Corporate Update -
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
03 juin 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Reports Results of 2024 Annual General Meeting
31 mai 2024 17h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Results of 2024 Annual General Meeting